.jpg)
BiomX's bacteria-killing virus reduces diabetic bone ulcers in midstage test
BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal has been shown to reduce uclers in a phase 2 study of patients with a diabetic foot infection.
BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal has been shown to reduce uclers in a phase 2 study of patients with a diabetic foot infection.
